Open Access Open Access  Restricted Access Subscription or Fee Access

Challenges and Perspectives of Peptide-Based Drug Development

Varsha Deshraj


With the number of small molecule-based drug candidates in clinical trials and approved drugs for the market decreasing, scientists from the pharmaceutical industry and academia are giving more attention to peptides or other bioactive drugs. Peptide drugs, especially the short synthetic and long-acting ones, are quickly increasing in the global market while advances in such fields as chemical synthesis and peptide formulation having been made in recent decades. The discovery of insulin in 1922 marked the beginning of research and development to improve the means of delivering protein therapeutics to patients. From that period forward, investigators have contemplated every possible route of delivery. Major hurdles remain in order to overcome the combined natural barriers of drug permeability, drug stability, pharmacokinetics and pharmacodynamics of protein therapeutics.

Full Text:



Reichert J (2010) Development Trends for Peptide Therapeutics (2010 Report Summary). Peptide Therapeutics Foundation: 1-10.

Lax R (2010) The Future of Peptide Development in the Pharmaceutical Industry. PharManufacturing: The International Peptide Review: 10-15.

Bellmann-Sickert K, Beck-Sickinger AG (2010) Peptide drugs to target G protein-coupled receptors. Trends Pharmacol Sci 31: 434-441.

Edwards CM, Cohen MA, Bloom SR (1999) Peptides as drugs. QJM 92: 1-4.

Khafagy el-S, Morishita M (2012) Oral biodrug delivery using cell-penetrating peptide. Adv Drug Deliv Rev 64: 531-539.

Reubi JC (2003) Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr Rev 24: 389-427.

Marx V (2005) Watching Peptide Drugs Grow up. C&EN 83: 17-24.

Rozenfeld R, Devi LA (2011) Exploring a role for heteromerization in GPCR signalling specificity. Biochem J 433: 11-18.


  • There are currently no refbacks.